Prevention of palmar–plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)
- 1 June 2014
- journal article
- research article
- Published by Elsevier in The Breast
- Vol. 23 (3) , 244-249
Abstract
No abstract availableKeywords
Funding Information
- Swiss Group of Clinical Cancer Research
- Spirig Pharma, Egerkingen
- ESSEX Chemie AG Luzern
- Swiss State Secretariat of Education and Research
This publication has 16 references indexed in Scilit:
- Clinical Presentation and Management of Hand–Foot Skin Reaction Associated with Sorafenib in Combination with Cytotoxic Chemotherapy: Experience in Breast CancerThe Oncologist, 2011
- Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trialAnnals of Oncology, 2011
- Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of expertsEuropean Journal of Cancer, 2008
- Palmar–plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centreEuropean Journal of Oncology Nursing, 2007
- Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome)Annals of Oncology, 2007
- A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)European Journal of Cancer, 2006
- Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?Annals of Oncology, 2005
- Detection of Doxorubicin in the Horny Layer in a Patient Suffering from Palmar-Plantar ErythrodysaesthesiaDermatology, 2005
- Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast CancerJournal of Clinical Oncology, 2004
- Chemotherapy-Induced Palmar-Plantar Erythrodysesthesia Syndrome: Etiology and Emerging TherapiesSupportive Cancer Therapy, 2004